CureVac AG, a company that has been active in the messenger RNA space for more than 16 years, is on the prowl for more pharma partners in order to advance its pipeline programs in prostate cancer and non-small cell lung cancer (NSCLC) to the next level and to widen its program into other indications.
Based in Germany, CureVac is one of the longest running mRNA development companies but the firm is facing increasing competition...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

